TB-500 (Thymosin Beta-4 Acetate)

TB-500 is a synthetic version of the LKKTETQ fragment of Thymosin Beta-4 — the biologically active actin-binding domain responsible for most of TBeta4's healing effects. Full Thymosin Beta-4 is more expensive and less available; TB-500 delivers the same key biological activity at lower cost.

Most researchers start with a loading phase of 4-6 mg twice weekly for 4-6 weeks, then reduce to 2-2.5 mg once or twice weekly for maintenance. The loading phase builds systemic levels rapidly during the active healing phase.

Both are healing peptides but through different mechanisms. BPC-157 primarily works via nitric oxide, angiogenesis, and growth factor upregulation with strong gut effects. TB-500 works primarily through actin dynamics, NF-kB inhibition, and cell migration. They complement each other excellently and are commonly combined in the BB Blend.

Yes — chronic injuries with suboptimal vascularisation and scar tissue are specifically addressable through TB-500's angiogenic and anti-adhesion effects. Researchers report meaningful improvement in long-standing injuries that have not fully resolved through standard rehabilitation.

Subcutaneous injection anywhere on the body is appropriate — TB-500 is systemically active. Some researchers inject near the injury site for additional local concentration, but systemic delivery is equally effective for most injuries.

TB-500 is generally well tolerated. The most commonly reported experience is mild fatigue on injection days during the loading phase, which resolves quickly. No clinically significant adverse effects have been consistently observed in research protocols.